Form 4: NewAmsterdam Pharma Executive Granted Stock Options

Juliette Berangere Audet, Chief Business Officer of NewAmsterdam Pharma, was granted options to purchase 100,000 ordinary shares.

Summary

• Juliette Berangere Audet, the Chief Business Officer of NewAmsterdam Pharma Co N.V., was granted options to purchase 100,000 ordinary shares.
• The options have an exercise price of $25.96 per share.
• The options vest over a four-year period, with 25% vesting on January 2, 2026, and the remainder vesting monthly over the following three years.
• The vesting is contingent upon Ms. Audet's continued employment with the company.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There are no negative implications.

Positives

• The granting of stock options aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Risks

• The value of the options is dependent on the future performance of the company's stock price.
• The executive must remain employed with the company to fully vest the options.

Future Outlook

The options will vest over the next four years, subject to the executive's continued employment.

Industry Context

Granting stock options is a common practice for incentivizing executives in the pharmaceutical industry.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for executives in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• Vesting schedules, such as the one described, are typical to ensure long-term commitment and alignment with company performance.
• The specific terms of the grant, such as the exercise price and vesting period, are generally determined based on the company's valuation and compensation strategy, and are comparable to those of similar companies.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the executive to improve company performance.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, executive compensation, vesting, equity, NAMS, NewAmsterdam Pharma, Chief Business Officer